Released Aug 14, 2013, after the close
10-Q filed Aug 14, 2013, 45 days after period end · 0001213900-13-004390
Q2 2013 · 10-Q
Revenue$5.58M$5.58M −25.0% vs Q2 2012+19.7% vs Q1 2013
Net Income$118.16K$118.16K −56.6% vs Q2 2012N/M vs Q1 2013
EPS Diluted$0.01$0.01 −50.0% vs Q2 2012N/M vs Q1 2013
Gross Profit$1,822,253−33.5%
Operating Income$149,690−90.0%
Operating Cash Flowderived-$134,582N/M
Free Cash Flowderived-$748,078N/M
Margins · derived
Gross margin32.7%−4.2 pt vs Q2 2012
Operating margin2.7%−17.5 pt vs Q2 2012
Net margin2.1%−1.5 pt vs Q2 2012
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2013 | Q2 2012 | Q2 2011 | Q2 2010 |
|---|---|---|---|---|
| Revenue | $5.58M | $7.43M | $4.99M | $4.27M |
| Net Income | $118.16K | $272.41K | -$1.65M | $568.26K |
| EPS Diluted | $0.01 | $0.02 | -$0.12 | $0.07 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tanke Biosciences Corp · CIK 1452011 · Engraved from SEC EDGAR